Chardan Capital Has Negative Outlook of UBX FY2025 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Research analysts at Chardan Capital lowered their FY2025 EPS estimates for Unity Biotechnology in a report released on Wednesday, April 23rd. Chardan Capital analyst D. Gataulin now expects that the company will earn ($0.91) per share for the year, down from their prior forecast of ($0.72). Chardan Capital has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. Chardan Capital also issued estimates for Unity Biotechnology’s FY2026 earnings at ($0.72) EPS.

Unity Biotechnology (NASDAQ:UBX) last announced its quarterly earnings results on Tuesday, April 22nd. The company reported ($0.43) EPS for the quarter, meeting analysts’ consensus estimates of ($0.43).

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Unity Biotechnology in a report on Wednesday, April 23rd.

Unity Biotechnology Price Performance

NASDAQ:UBX opened at $0.98 on Monday. The firm has a market capitalization of $16.48 million, a price-to-earnings ratio of -0.75 and a beta of 1.30. The business has a 50 day simple moving average of $1.35 and a 200-day simple moving average of $1.43. Unity Biotechnology has a 1 year low of $0.85 and a 1 year high of $3.10.

Institutional Trading of Unity Biotechnology

Several institutional investors have recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC bought a new position in shares of Unity Biotechnology during the first quarter valued at approximately $29,000. Bridgeway Capital Management LLC lifted its stake in shares of Unity Biotechnology by 100.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 50,000 shares of the company’s stock worth $49,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Unity Biotechnology by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 163,242 shares of the company’s stock valued at $240,000 after acquiring an additional 14,199 shares during the period. Institutional investors own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.